ClinicalTrials.gg
RecruitingNCT04921020Updated Jun 10, 2021

Assessment of Eyelid Topology and Kinetics Based on Deep Learning Method

An observational study in Eyelid Diseases, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
500
Sex
All
01

Study summary

This study plans to assess eyelid topology (such as margin reflex distance, eyelid contour, and corneal exposure area) and blinking (such as frequency, velocity, and duration), using deep learning method to automatically extract eyelid topological features, and to predict subtypes of levator function, using deep learning method to extract blinking features, in order to provide new ideas and means to assess eyelid topology and kinetics.

02

Conditions studied

  • Eyelid Diseases

Browse trials for

03

In context

Eyelid Diseases

26 studies on the registry are indexed under Eyelid Diseases; 4 are open to participants now.

Browse Eyelid Diseases studies →

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

100 normal volunteers without eyelid diseases 100 patients with blepharoptosis 100 patients with blepharospasm 100 patients with dry eye disease 100 patients with Graves' disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. normal volunteers without eyelid diseases
  2. patients with blepharoptosis
  3. patients with blepharospasm
  4. patients with dry eye disease
  5. patients with Graves' disease

Exclusion criteria

Exclusion Criteria:

variable ptosis (e.g., myasthenia gravis), entropion, ectropion, enophthalmos, exophthalmos, strabismus, and abnormalities of pupil

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal participants

    Other: Photography

  • Patients with blepharoptosis

    Other: Photography

  • Patients with blepharospasm

    Other: Photography

  • Patients with dry eye disease

    Other: Photography

  • Patients with Graves' disease

    Other: Photography

Interventions

  • OtherPhotography

    Facial photographs and blinking videos are taken

06

What researchers measure

Primary outcomes

  1. one-dimensional parameters of eyelid topology

    Palpebral fissure length \[Margin reflex distance 1, Margin reflex distance 2\], Lid length \[Upper lid length, Lower lid length\], Multiple mid-pupil lid distances

    Time frame: through study completion, 5 years

  2. two-dimensional parameters of eyelid topology

    Palpebral fissure area \[Medial area, Corneal area, Lateral area\]

    Time frame: through study completion, 5 years

  3. subtypes of levator function

    Levator function is classified into three categories: good, fair and poor

    Time frame: through study completion, 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Aug 2025, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jun 10, 2021
StartActual
Aug 1, 2020
Primary completionEst.
Aug 1, 2025
CompletionEst.
Aug 1, 2026
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04921020
Responsible party
Sponsor
First posted
Jun 10, 2021
Start date
Aug 1, 2020
Primary completion
Aug 1, 2025 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Jun 10, 2021

Study contacts

Juan Ye
Contact
yejuan@zju.edu.cn
+86-571-87783897
Lixia Lou
Contact
loulixia110@zju.edu.cn
+86-15088681589

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion